Skip to main content
. Author manuscript; available in PMC: 2022 Nov 26.
Published in final edited form as: N Engl J Med. 2022 May 26;386(21):1998–2010. doi: 10.1056/NEJMoa2119771

Figure 1. Increased SALL4 Expression in Patients with Myelodysplastic Syndrome after Treatment with a Hypomethylating Agent.

Figure 1.

Panel A shows a waterfall plot of the log2 factor change in SALL4 expression in 25 patients after four cycles of azacytidine treatment in cohort 1. Panel B shows a waterfall plot of the log2 factor change in SALL4 expression in 43 patients after three to five cycles of treatment with a hypomethylating agent in cohort 2. The term t0 denotes before any cycles of treatment, and t4 after four cycles of treatment. Panel C shows overall survival among patients with SALL4 up-regulation and those with SALL4 down-regulation in cohort 1, and Panel D shows the corresponding data in cohort 2. In Panels C and D, tick marks indicate censored data. A log-rank test was used to compare survival curves for statistical significance in Panels C and D.